Condition: Melanoma (Skin) · Triple-Negative Breast Cancer · Non-Small Cell Lung Cancer · Sponsor: Valo Therapeutics Oy
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.
This description comes directly from the study's public registry record.
Kuryk, PhD · 0505876088 · info@valotx.com
Always discuss trial participation with your own doctor first.
| Krankenhaus Nordwest | Frankfurt, Germany | Active Not Recruiting |
| National Center for Tumor Diseases | Heidelberg, Germany | Completed |
| Universitätsklinikum Tübingen | Tübingen, Germany | Completed |
| Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS | Candiolo, Italy | Recruiting |
| IRCCS Istituto Clinico Humanitas | Milan, Italy | Not Yet Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Not Yet Recruiting |
| Università di Napoli Federico II | Naples, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05492682